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Abstract: The overexpression of gastrin-releasing peptide receptors (GRPRs) in frequently occurring
human tumors has provided the opportunity to use bombesin (BBN) analogs as radionuclide
carriers to cancer sites for diagnostic and therapeutic purposes. We have been alternatively exploring
human GRP motifs of higher GRPR selectivity compared to frog BBN sequences aiming to improve
pharmacokinetic profiles. In the present study, we compared two differently truncated human
endogenous GRP motifs: GRP(14–27) and GRP(18–27). An acyclic tetraamine was coupled at the
N-terminus to allow for stable binding of the SPECT radionuclide 99mTc. Their biological profiles
were compared in PC-3 cells and in mice without or with coinjection of phosphoramidon (PA) to
induce transient neprilysin (NEP) inhibition in vivo. The two 99mTc-N4-GRP(14/18–27) radioligands
displayed similar biological behavior in mice. Coinjection of PA exerted a profound effect on in vivo
stability and translated into notably improved radiolabel localization in PC-3 experimental tumors.
Hence, this study has shown that promising 99mTc-radiotracers for SPECT imaging may indeed
derive from human GRP sequences. Radiotracer bioavailability was found to be of major significance.
It could be improved during in situ NEP inhibition resulting in drastically enhanced uptake in
GRPR-expressing lesions.
Keywords: bombesin; gastrin-releasing peptide; gastrin-releasing peptide receptor; tumor targeting;
99mTc-radioligand; metabolic stability; neprilysin-inhibition; phosphoramidon
1. Introduction
Gastrin-releasing peptide receptors (GRPRs) are overexpressed in several human malignancies
such as prostate cancer, mammary carcinoma, and lung cancer [1–10]. Consequently, they have
attracted considerable attention as potential biomolecular targets for diagnosis and therapy
with radionuclide carriers directed to GRPR-positive cancer lesions [11,12]. Originally, the frog
tetradecapeptide bombesin (BBN, Pyr-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2)
and its truncated C-terminal octapeptide fragment BBN(7–14) have served as motifs for the
development of GRPR-targeting radioligands. However, BBN-like analogs bind with comparable
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affinity not only to GRPR (BB2R), but also to the neuromedin B (NMBR, BB1R), another
member of the three mammalian bombesin receptor subtypes [1,2]. The above two subtypes
are pharmacologically distinguished by their selectivity for different endogenous human
homologs of amphibian BBN. Thus, the 27-mer GRP (H-Val-Pro-Leu-Pro-Ala-Gly-Gly-Gly-Thr-
Val-Leu-Thr-Lys-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2), the 14-mer
GRP(14–27), and the C-terminal decapeptide GRP(18–27) fragments strongly bind to the GRPR,
whereas neuromedin B (NMB, H-Gly-Asn-Leu-Trp-Ala-Thr-Gly-His-Phe-Met-NH2) exhibits high
affinity for the NMBR [13]. The two GRPR and NMBR subtypes are physiologically expressed in the
human brain and the gut, especially in stomach, pancreas, and gastrointestinal tract, and they are
also implicated in cancer [14–16]. It is reasonable to assume, that radiolabeled BBN agonists of poor
GRPR selectivity will show increased levels of background radioactivity by virtue of their binding to
both GRPR and NMBR populations distributed in the body, especially in the abdomen. Furthermore,
additive GRPR- and NMBR-mediated effects in the gastrointestinal tract, such as abdominal smooth
muscle contraction and stimulation of gastrointestinal hormone secretion, are to be expected after
intravenous injection of BBN-like agonist radioligands [17–22].
In contrast to amphibian BBN-like motifs, the respective human homologs have surprisingly
remained unexploited as radionuclide carriers for targeting GRPR-positive cancer [13]. Motivated by
this gap in the inventory of GRPR-directed radioligands we have expanded our research efforts to
native human GRP sequences in order to explore their applicability in GRPR-targeted tumor diagnosis
and therapy. First, we introduced a small library of tetraamine derivatized GRP(18–27) analogs labeled
with the SPECT radionuclide 99mTc [23,24]. Compared to previously reported 99mTc-radiopeptides,
which are based on the full-length BBN or its truncated BBN(7–14) octapeptide fragment [25],
the 99mTc-N4-GRP(18–27) showed high GRPR selectivity and superior in vivo characteristics in
tumor-bearing mice, such as faster renal clearance and improved tumor to background ratios.
On the other hand, single or double amino acid substitutions in the decapeptide backbone exerted
pronounced effects on several biological properties, eventually affecting tumor targeting capabilities
and pharmacokinetics. In a following study, a series of differently truncated GRP sequences were
coupled to the universal chelator DOTA (1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid) and
labeled with 111In. Receptor affinity, internalization efficiency and tumor uptake of these analogs were
favored both by longer peptide chain and by the presence of basic amino acids Lys13 and Arg17 in the
native GRP sequence [26].
Following this line of research, we herein introduced 99mTc-N4-GRP(14–27) and compared its
biological profile in PC-3 cells and mice models with 99mTc-N4-GRP(18–27) (Figure 1). It should
be noted that basic positions Lys13 and Arg17 in the native GRP sequence are now occupied by
the positively charged N4+x/[99mTc(O)2(N4)]+1-moiety and not by the negatively charged DOTA.
This arrangement allows for comparisons with the DOTA-derivatized analogs and further studying
the influence of positive/negative charges in 13 and 17 positions of the GRP chain [26]. Next,
the selectivity of N4-GRP(14–27) for each of the three mammalian bombesin receptor subtypes was
investigated applying receptor autoradiography in human excised biopsy samples, expressing one of
the GRPR, NMBR, and bombesin subtype 3 (BB3R) receptors. Finally, the impact of in vivo stability
of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) on tumor targeting and pharmacokinetics was
compared in mice. The role of neprilysin (NEP) [27] on the in vivo degradation of the two human
GRP-based sequences was monitored by HPLC analysis of blood samples collected without or with
coinjection of the NEP-inhibitor phosphoramidon (PA) [28,29], as previously described for BBN-like
radioligands [30–34]. The enhancement of radiotracer localization in experimental GRPR-positive
PC-3 tumors in mice during transient NEP inhibition induced by PA was assessed.
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Figure 1. Chemical structure of (a) 99mTc-N4-GRP(14–27) (red) and (b) 99mTc-N4-GRP(18–27) (blue).
2. Results
2.1. Peptides and Radioligands
The bifunctional acyclic tetraamine chelator (6-(carboxy)-1,4,8,11-tetraazaundecane) was
covalently coupled by its carboxy functionality at the N-terminal Met14 of GRP(14–27) or the Gly18
of GRP(18–27) via an amide bond [24], generating two different length GRP analogs amenable
for labeling with the preeminent SPECT radionuclide 99mTc. Labeling was typically proceeded by
a brief incubation with 99mTcO4− generator eluate, SnCl2 as reducing agent, and citrate anions as
transfer ligand in alkaline pH at ambient temperature at molar activities of 20 to 40 MBq 99mTc/nmol
peptide. Quality control of the radiolabeled products combined HPLC and ITLC analysis. The total
radiochemical impurities, comprising 99mTcO4−, [99mTc] citrate, and 99mTcO2 × H2O, did not exceed
2%, while a single radiopeptide species was detected by RP-HPLC. In view of labeling yields >98%
and >99% radiochemical purity of the resultant 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27),
the radioligands were used without further purification in all subsequent experiments. Representative
radiochromatograms of HPLC analysis of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) are included
in Figure 2a,b, respectively.
Figure 2. Representative radiochromatograms of the radiolabeling reaction mixture of
(a) 99mTc-N4-GRP(14–27) (red) and (b) 99mTc-N4-GRP(18–27) (blue), confirming the quantitative
formation of high purity radioligands at tR = 14.9 min and tR = 13.3 min, respectively (HPLC system 1).
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2.2. In Vitro Assays
2.2.1. Receptor Autoradiography in Human Tumor Samples
The selective affinities of N4-GRP(14–27) for each of the three bombesin receptor subtypes
found in mammals were studied during in vitro competition binding assays against the universal
radioligand 125I-[DTyr6,βAla11,Phe13,Nle14]BBN(6–14) [6]. Receptor autoradiography was applied
in cryostat sections of well characterized human cancers, preferentially expressing one of the
subtypes. As summarized in Table 1, N4-GRP(14–27) showed high affinity for the GRPR expressed
in resected prostate carcinoma specimens (IC50 = 4.2 ± 1.0 nM, n = 3, vs. IC50 = 2.4 ± 1.0 nM,
n = 3 for N4-GRP(18–27) [23]), very low affinity for NMBR present in ileal carcinoid biopsy samples
(IC50 = 72± 7.6 nM, n = 3, vs. IC50 = 106± 13 nM; n = 2 for N4-GRP(18–27) [23]), and no affinity for the
BB3R expressed in bronchial carcinoid samples (IC50 > 1000 nM, n = 3, identical to N4-GRP(18–27) [23]).
Thus, N4-GRP(14–27) similarly to N4-GRP(18–27), displayed good selectivity for the GRPR. Hence,
the GRP-based analogs turned out to be more GRPR-preferring compared to BBN-based radioligands,
like Demobesin 3 (N4-[Pro1,Tyr4]BBN) [25] or [DTyr6,βAla11,Phe13,Nle14]BBN(6–14) (Table 1).
Table 1. Affinities for the three human bombesin receptor subtypes.
Peptide Conjugate
IC50s in nM
GRPR 1 NMBR 2 BB3R 3
Universal ligand 4 1.5 ± 0.1 (3) 1.5 ± 0.2 (3) 3.5 ± 0.7 (3)
N4-GRP(14–27) 4.2 ± 1.0 (3) 72 ± 7.6 (3) >1000 (3)
N4-GRP(18–27) 2.4 ± 1.0 (3) 106 ± 13 (2) >1000 (3)
Demobesin 3 0.5 (2) 1.6 (2) >100 (3)
The data represents the mean (±SEM; n = 3) for the cold universal ligand and for the two N4-GRP(14/18–27) analogs
and the mean (n = 2) for Demobesin 3. 125I[DTyr6,βAla11, Phe13,Nle14]BBN(6–14) was used as radioligand in all
experiments; 1 expressed in human prostate cancer, 2 in human ileal carcinoids and 3 in human lung carcinoids,
4[DTyr6,βAla11,Phe13,Nle14]BBN(6–14) was used as cold universal ligand.
2.2.2. Binding Affinity for the Human GRPR
As shown in Figure 3a, N4-GRP(14–27) and N4-GRP(18–27) as well as the respective GRP(14–27)
and GRP(18–27) parent peptide references displaced [125I-Tyr4]BBN from GRPR-sites on PC-3 cell
membranes in a monophasic and dose-dependent manner. The respective half-maximal inhibitory
concentration (IC50) values differed, yielding the following rank of decreasing receptor affinity:
N4-GRP(14–27) (IC50 0.32 ± 0.03 nM) > GRP(14–27) (IC50 0.45 ± 0.02 nM) > N4-GRP(18–27)
(IC50 0.63 ± 0.06 nM) > GRP(18–27) (IC50 1.66 ± 0.20 nM). We observe that the longer-chain peptides
consistently showed higher binding affinity to GRPR than their shorter chain counterparts. Moreover,
coupling of the positively charged acyclic tetraamine unit in the N-terminus of parent GRP(14/18–27)
references improved the affinity of resulting analogs to the GRPR, as previously reported for similarly
modified peptide analogs [35].
2.2.3. Internalization of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) in PC-3 Cells
During incubation at 37 ◦C in PC-3 cells, both 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27)
were taken up by the cells via a GRPR-mediated process, as demonstrated by the lack of internalization
observed in the presence of excess [Tyr4]BBN. In both cases the bulk of cell-associated radioactivity
was found in the cells with 99mTc-N4-GRP(14–27) internalizing much faster in PC-3 cells compared to
99mTc-N4-GRP(18–27) at all time intervals (Figure 3b). For example, at 1 h, 12.7 ± 0.7% of total added
99mTc-N4-GRP(14–27) specifically internalized in the cells vs. 5.0 ± 0.3% of 99mTc-N4-GRP(18–27),
whereas at 2 h these values increased to 19.5 ± 1.4% and 6.9 ± 1.5%, respectively.
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Figure 3. (a) [125I-Tyr4]BBN displacement curves from gastrin-releasing peptide receptor (GRPR)-sites
on PC-3 cells after 1-h incubation at 22 ◦C by N4-GRP(14–27) (red solid line—IC50 0.32±0.03 nM),
GRP(14–27) (red dashed line—IC50 0.45 ± 0.02 nM), N4-GRP(18–27) (blue solid line—IC50 0.63±0.06
nM) and GRP(18–27) (blue dashed line—IC50 1.66 ± 0.20 nM). (b) GRPR-specific internalization of
99mTc-N4-GRP(14–27) (red solid line) and 99mTc-N4-GRP(18–27) (blue solid line) in PC-3 cells during
incubation at 37 ◦C at 15, 30, 60, and 120 min. Results represent average of cell internalized activity ± sd,
n = 3; data is corrected for nonspecific internalization in the presence of 1 µM [Tyr4]BBN.
2.3. In Vivo Comparison of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27)
2.3.1. Stability of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) in Mice
The two 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) radiotracers exhibited distinct resistance
to degrading proteases after injection in mice. As revealed by HPLC analysis of blood samples collected
at 5 min postinjection (pi), 99mTc-N4-GRP(14–27) was found less stable (20.1 ± 4.5% intact, n = 3) than
the shorter chain 99mTc-N4-GRP(18–27) (31.0± 0.9% intact, n = 3). Representative radiochromatograms
are shown in Figure 4a,b, respectively.
Figure 4. Representative radiochromatograms of HPLC analysis of mouse blood samples collected 5 min
pi of (a) 99mTc-N4-GRP(14–27) (25.2% intact radiotracer; red dashed line) or (b) 99mTc-N4-GRP(18–27)
(31.8% intact radiotracer; blue dashed line) without PA coinjection; the respective radiochromatograms of
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(c) 99mTc-N4-GRP(14–27) (63.1% intact radiotracer; tR = 29.6 min; red solid line) or (d) 99mTc-N4-GRP(18–27)
(68.1% intact radiotracer; tR = 25.1 min; blue solid line) with PA coinjection are also included; the tR of
parent radiopeptide was determined by coinjection with the respective radioligand sample in the column
(HPLC system 2) and is indicated here by the arrow.
It should be noted that coinjection of the NEP-inhibitor PA remarkably enhanced the in vivo
stability of 99mTc-N4-GRP(14–27) (66.5 ± 4.8% intact, n = 3) and 99mTc-N4-GRP(18–27) (70.8 ± 5.4%
intact, n = 3) in the circulation, revealing NEP as a major degrading protease for both radiotracers in
mice. Representative radiochromatograms are included in Figure 4c,d, respectively.
2.3.2. Biodistribution in PC-3 Xenograft-Bearing Mice
The biodistribution of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) was studied in severe
combined immune deficiency (SCID) mice bearing human PC-3 xenografts expressing the human
GRPR. Subcutaneous tumors of suitable size developed in the flanks of mice about four weeks after
inoculation of a suspension of prostate adenocarcinoma PC-3 cells and biodistribution was conducted.
Cumulative biodistribution results for 99mTc-N4-GRP(14–27) at the 1-, 4-, and 24-h pi intervals are
summarized in Table 2, and are expressed as mean % injected dose per gram (%ID/g) values ± sd,
n = 4. The radiotracer washed rapidly from the blood and the background tissues predominantly
via the kidneys and the urinary system. High uptake was observed in the PC-3 tumor at 1-h pi
(10.20 ± 0.72%ID/g) that remained at comparably high levels at 4-h pi (8.41 ± 4.16%ID/g; p > 0.05),
declining by ~50% at 24-h pi (4.50 ± 0.69%ID/g). Tumor uptake at 4-h pi was significantly lower in the
animals treated with excess [Tyr4]BBN (0.62 ± 0.24%ID/g; p < 0.001), suggestive of a GRPR-mediated
process. Likewise, 99mTc-N4-GRP(14–27) highly localized in the GRPR-rich mouse pancreas via
a GRPR-specific process, as demonstrated by the lack of pancreatic uptake during GRPR-blockade by
coinjection of excess [Tyr4]BBN (35.24 ± 4.70%ID/g vs. 0.83 ± 0.24%ID/g in block; p < 0.001).
Table 2. Biodistribution data for 99mTc-N4-GRP(14–27), expressed as %ID/g mean ± sd, n = 4, in PC-3
xenograft-bearing SCID mice at 1-h, 4-h block, 4-h, and 24-h pi.
Tissue 1 h 1 4 h 1 24 h 1 4 h block 2
Blood 1.54 ± 0.17 0.10 ± 0.03 0.07 ± 0.01 0.08 ± 0.02
Liver 5.02 ± 0.46 3.75 ± 1.11 3.23 ± 0.78 6.12 ± 2.89
Heart 0.70 ± 0.07 0.11 ± 0.04 0.07 ± 0.01 0.28 ± 0.13
Kidneys 14.82 ± 2.22 4.83 ± 2.12 3.10 ± 0.73 4.85 ± 2.66
Stomach 1.02 ± 0.29 1.42 ± 0.93 0.78 ± 0.33 0.43 ± 0.18
Intestines 7.21 ± 0.52 7.61 ± 2.23 1.73 ± 0.23 1.45 ± 0.44
Muscle 0.29 ± 0.02 0.03 ± 0.01 0.06 ± 0.01 0.05 ± 0.02
Lungs 1.96 ± 0.33 0.49 ± 0.30 0.18 ± 0.04 0.65 ± 0.22
Pancreas 37.85 ± 1.95 35.24 ± 4.70 13.41 ± 0.77 0.83 ± 0.24
Tumor 10.20 ± 0.72 8.41 ± 4.16 4.50 ± 0.69 0.62 ± 0.24
1 Animal groups injected with 180–370 kBq/10 pmol peptide; 2 block mice group coinjected with 40 nmol [Tyr4]
BBN for in vivo GRPR blockade.
Comparative biodistribution results for 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) at the
4-h pi interval are included in Table 3. Data from additional 4-h pi animal groups coinjected with
the NEP-inhibitor PA (300 µg) is also included in the Table. The radiotracers displayed similar tissue
distribution patterns. The observed higher tumor and pancreatic uptake of 99mTc-N4-GRP(14–27)
did not however differ significantly to that of 99mTc-N4-GRP(18–27) (p > 0.05) [24]. Treatment with
PA induced a drastic increase in tumor values for both radiotracers with 99mTc-N4-GRP(14–27)
showing superior tumor values than the shorter chain 99mTc-N4-GRP(18–27) (38.19 ± 4.79%ID/g vs.
28.37 ± 8.05%ID/g, respectively; p < 0.01). Pancreatic values increased by >3-fold for both radiotracers
as well. Thus, in agreement with previous studies on BBN-based analogs [31–34], NEP inhibition
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likewise resulted in significant stabilization of GRP(14/18–27)-based radioligands in peripheral mouse
blood and notable improvement of localization in GRPR-expressing lesions in mice.
Table 3. Comparative biodistribution data for 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27),
expressed as %ID/g mean ± sd, n = 4, in PC-3 xenograft-bearing SCID mice at 4-h pi (controls)
and 4-h pi after coinjection of PA.
Tissue
99mTc-N4-GRP(14–27) 99mTc-N4-GRP(18–27)
4 h 1 4 h PA 1,2 4 h1 4 h PA 1,2
Blood 0.10 ± 0.03 0.23 ± 0.08 0.13 ± 0.04 0.21 ± 0.04
Liver 3.75 ± 1.11 4.99 ± 1.53 1.02 ± 0.17 2.13 ± 0.37
Heart 0.11 ± 0.04 0.89 ± 0.06 0.14 ± 0.10 0.47 ± 0.27
Kidneys 4.83 ± 2.12 11.68 ± 1.61 6.01 ± 1.38 7.66 ± 1.39
Stomach 1.42 ± 0.93 3.82 ± 1.10 1.12 ± 0.75 4.02 ± 0.66
Intestines 7.61 ± 2.23 21.35 ± 1.68 7.28 ± 0.60 16.23 ± 3.90
Muscle 0.03 ± 0.01 0.06 ± 0.02 0.03 ± 0.01 0.06 ± 0.01
Lungs 0.49 ± 0.30 1.06 ± 0.19 0.28 ± 0.09 0.84 ± 0.26
Pancreas 35.24 ± 4.70 110.32 ± 8.76 32.18 ± 5.91 95.39 ± 20.34
Tumor 8.41 ± 4.16 38.19 ± 4.79 7.08 ± 1.29 28.37 ± 8.05
1 Animal groups injected with 180–370 kBq/10 pmol peptide; 2 PA mice groups with animals coinjected with 300 µg
PA to in situ inhibit NEP.
3. Discussion
A considerable number of radiolabeled analogs of frog BBN have been developed for potential
application in the diagnosis and therapy of GRPR-expressing tumors in Homo sapiens [11,12].
This pursuit is based on the overexpression of GRPRs on the surface of malignant cells serving as
easily accessible biomolecular targets on cancer lesions [3–10]. Joining this effort, we have previously
introduced a series of BBN-like analogs, generated by covalently coupling of an acyclic tetraamine at the
N-terminus, Demobesin 3–6 [25]. Like native BBN, these peptide ligands displayed indistinguishable
binding affinities for the human bombesin receptor subtypes GRPR and NMBR, but no affinity for the
BB3R. The respective radiotracers [99mTc] Demobesin 3–6 specifically localized in GRPR-expressing
human PC-3 xenografts in mice. Moreover, one of the analogs, [99mTc] Demobesin 4, was able to
visualize malignant lesions in a small number of prostate cancer patients with SPECT/CT [36].
We have recently expanded our search toward radioligands based on human endogenous GRP
sequences [23,24,26]. The latter are reported for higher GRPR selectivity compared to their frog
homolog BBN [13]. This approach has surprisingly remained unexplored up to now, although it
offers two major advantages. First, radioactivity levels in abdominal tissues physiologically
expressing both GRPR and NMBR subtypes would favorably decrease when GRPR-selective
radioligands are used [14–16]. Second, injection of GRPR-selective agonists will not activate the
NMBR subtype populations in the gut and is hence associated with less adverse effects [17–22].
Promising GRPR-selective radioligands based on receptor antagonists have been developed and
evaluated in animals and in human, showing excellent tumor targeting and pharmacokinetic
profiles [37,38]. Yet, the suitability and efficacy of noninternalizing GRPR antagonists for therapy
with low-range beta, alpha, or Auger emitters of high LET has not been established thus far [39,40].
Therefore, the study of radiolabeled GRPR-selective agonists is warranted and may provide
an alternative platform for the development of radioligands exhibiting new combinations of biological
features particularly suited for cancer theranostics.
As a part of this effort we herein introduced two analogs of endogenous truncated fragments
of human GRP carrying an acyclic tetraamine at their terminus, one based on the tetradecapeptide
GRP(14–27), and the other on a shorter decapeptide GRP(18–27) chain identical to human neuromedin
C (NMC) (Figure 1). As revealed during receptor autoradiography studies in excised biopsy samples
of well characterized human tumors expressing each of the GRPR, NMBR, and BB3R subtypes
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using the universal 125I-[DTyr6,βAla11,Phe13,Nle14]BBN(6–14) radioligand, both N4-GRP(14–27) and
N4-GRP(18–27) analogs showed good selectivity for the GRPR subtype (Table 1). This finding is
in agreement with previous reports documenting the preference of human GRP and its C-terminal
native fragments for GRPR [13]. In contrast, the tetraamine derivatized BBN-like analogs Demobesin
3–6 do not distinguish between GRPR and NMBR, instead behaving like the native frog BBN [25].
The His20 of GRP corresponding to Gln7 of BBN seems to have significant impact on subtype
selectivity, followed by the Met14-Tyr13-Pro12-Arg11-tetrapeptide in GRP(14–27) corresponding to
the Pyr1-Gln2-Arg3-Leu4-counterpart in native BBN.
Both N4-GRP(14–27) and N4-GRP(18–27) analogs displayed sub-nM affinities for the GRPR during
competition assays against [125I-Tyr4]BBN in PC-3 cell membranes, which were found to be increased
compared to unmodified GRP(14/18–27) lead structures (Figure 3a). It is interesting to note that the
presence of the positively charged N4+x-moiety at positions 13 and 17 of the native GRP chain occupy
the two basic amino acids Lys13 and Arg17. When these positions were taken up by negatively charged
DOTA instead, a drastic drop in binding affinity was observed (IC50 DOTA-GRP(14–27) = 6.6 ± 0.9 nM
and IC50 DOTA-GRP(18–27) = 112 ± 16 nM) [26]. In all cases, longer chain GRP(14–27) analogs
consistently displayed higher GRPR-affinity compared to their C-terminal decapeptide counterparts.
In agreement with this observation, the internalization rate of 99mTc-N4-GRP(14–27) in PC-3 cells was
clearly superior to that of 99mTc-N4-GRP(18–27) (Figure 3b).
A crucial feature for efficient tumor targeting is metabolic stability that will ensure sufficient
radioligand supply to tumor sites after injection in the living organism [31]. Recent studies have revealed
the significance of in vivo stability assessment of BBN-like radiotracers vs. in vitro determinations in
serum or tissue homogenate incubates to more accurately predict the actual protease(s) encountered
by the radioligand after entering the circulation. These studies have demonstrated NEP as a major
degrading protease of BBN and its radiolabeled analogs [41,42]. In a recently proposed approach,
NEP-inhibitors, like PA [28,29], coinjected with the BBN-based radioligand drastically increased
metabolic stability leading to notable enhancement of tumor uptake in animal models [31–34].
Following this rationale, we have tested the in vivo stability of the two 99mTc-N4-GRP(14–27) and
99mTc-N4-GRP(18–27) radiotracers in peripheral mouse blood collected 5 min pi by radioanalytical
HPLC (Figure 4). The longer chain 99mTc-N4-GRP(14–27) displayed somewhat poorer stability
(20.1 ± 4.5% intact, n = 3) compared to shorter chain 99mTc-N4-GRP(18–27) (31.0 ± 0.9% intact, n = 3).
Thus, the presence of additional amide bonds in the longer peptide chain offered further degradation
sites for attacking proteases. It is interesting to note, that coinjection of PA drastically increased the
stability of both analogs in the circulation, indicating NEP as a major protease in the catabolism of
GRP sequences as well.
Aiming to explore the effects of peptide chain as well as NEP inhibition on the pharmacokinetics
and tumor targeting capabilities of the two tracers, we have conducted biodistribution experiments in
immunosuppressed mice bearing human GRPR-expressing xenografts. Interestingly, the biodistribution
patterns of the two radiotracers did not clearly differ (Table 3). Compared to the previously reported
111In-DOTA analogs [26], 99mTc-N4-GRP(14–27) showed higher tumor uptake. Comparable in vivo
tumor targeting was obtained only by 111In-DOTA-GRP(13–27), carrying basic Lys at position 13.
However, kidney clearance was notably faster for the 99mTc-radiotracer (4.83 ± 2.12%/g at 4 h pi)
than for the 111In-DOTA-Lys13-analog (46.02 ± 3.73%/g at 4 h pi) [26]. Treatment of mice with PA
exerted a profound effect on the in vivo profile of both 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27)
(Table 2), is in agreement with previous findings for other BBN-like radioligands. The longer chain
99mTc-N4-GRP(14–27) exhibited the highest uptake in the experimental tumor, as a combined result of
higher internalization rate and pronounced in vivo stabilization induced by PA.
The present study has shown that GRP motifs of different chain length may provide new
opportunities for the development of promising GRPR-selective radioligands. The latter may prove to
be a useful asset in the arsenal of anti-GRPR radioactive drugs, by internalizing in cancer cells while
evading binding to and activation of bombesin receptor subtypes other than the GRPR in the gut.
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Furthermore, it has shown the impact of in vivo metabolic stability in maximizing tumor localization.
Structural modifications in peptide lead-structures to improve the stability of radiopeptides, such as
amino acid replacements, cyclization, or changes of cleavable peptide bonds, may deteriorate other
important biological features, as for example receptor affinity, cell uptake, tumor targeting, and overall
pharmacokinetics. On the other hand, transient in situ inhibition of NEP represents a smart method
to accomplish this goal and warrants further efforts for translation in the clinic. Despite challenges
related to biosafety, regulatory and financial hurdles, once established in a proof-of-principal study,
this strategy is expected to boost the development and clinical application of other NEP-catabolized
radioligands, considerably saving costs and resources [31–34].
4. Materials and Methods
4.1. Peptides and Reagents
The N4-GRP(14–27) and N4-GRP(18–27) peptide conjugates were synthesized on the solid
support following a published method [24] and were provided by PiChem (Graz, Austria).
The [Tyr4]BBN (Tyr4-bombesin, Pyr-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2)
and GRP(14–27) (H-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2) references
were purchased from PSL GmbH (Heidelberg, Germany), whereas GRP(18–27) (H-Gly-Asn-His-Trp-Ala-
Val-Gly-His-Leu-Met-NH2) was provided by PeptaNova GmbH (Sandhousen, Germany). Phosphoramidon
disodium dehydrate (N-(α-rhamnopyranosyloxyhydro xyphosphinyl) -L-leucyl-L-tryptophan× 2Na×
2H2O; PA) was purchased from PeptaNova GmbH (Sandhousen, Germany).
Preparation and Quality Control of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27)
Lyophilized N4-GRP(14–27) and N4-GRP(18–27) were dissolved in bidistilled water to a final
1 mM concentration and bulk solutions were distributed in 50 µL aliquots in Eppendorf vials (Protein
LoBind Tube 1.5 mL; Eppendorf AG, Hamburg, Germany) and stored at −20 ◦C. For 99mTc labeling,
the following solutions were added into an Eppendorf tube containing 0.5 M phosphate buffer pH 11.5
(25 µL): 0.1 M sodium citrate (3 µL), [99mTc]NaTcO4 (210 µL, 150–300 MBq) eluted from a commercial
99Mo/99mTc generator (Ultratechnekow, Tyco Healthcare, Petten, The Netherlands), N4-GRP(14–27) or
N4-GRP(18–27) stock solution (7.5 µL, 7.5 nmol), and finally, fresh SnCl2 solution in EtOH (5 µg, 5 µL).
After 30 min incubation at ambient temperature the reaction mixture was neutralized by addition of
1 M HCl (4 µL) and EtOH was added (25 µL).
Quality control of the radiolabeled products comprised radioanalytical HPLC and instant
thin-layer chromatography (ITLC). HPLC analyses were performed on a Waters Chromatograph
coupled to a 2998 photodiode array UV detector (Waters, Vienna, Austria) and a Gabi gamma
detector (Raytest RSM Analytische Instrumente GmbH, Germany). For analysis, a Waters Symmetry
Shield RP-18 cartridge column (5 µm, 3.9 mm × 20 mm) was eluted at a 1.0 mL/min flow rate with
the following gradient, 0% B to 40% B in 20 min, where A = 0.1% aq. trifluoroacetic acid (TFA),
B = MeCN (System 1). Under these conditions 99mTcO4− eluted at 1.8 min and 99mTc-N4-GRP(14–27)
and 99mTc-N4-GRP(18–27) with a tR > 12 min. For the detection of reduced hydrolyzed technetium
(99mTcO2·× H2O) ITLC was conducted on ITLC-SG strips (Pall Corporation, New York, NY, USA),
as previously described. The resultant 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) radioligands
were used without further purification in all subsequent experiments.
Radioiodination of [Tyr4]BBN was performed using 125I ([125I]NaI in 0.1 N NaOH (pH 12–14)
provided by MDS Nordion, Ottawa, ON, Canada) according to the chloramine-T methodology,
as previously described [34]. Methionine was added to the purified radioligand solution to prevent
reoxidation of Met14 to the corresponding sulfoxide and the resulting stock solution in 0.1% BSA-PBS
was kept at −20 ◦C; aliquots thereof were used in competition binding assays (molar activity of
81.4 GBq/µmol).
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4.2. In Vitro Assays
4.2.1. Cell Lines and Culture
Human androgen-independent prostate adenocarcinoma PC-3 cells endogenously expressing
the human GRPR (LGC Promochem, Teddington, UK) were used in the present study [43]. Cells
were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium, supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin, and kept
in a controlled humidified atmosphere containing 5% CO2 at 37 ◦C. Passages were performed weekly
using a trypsin/EDTA (0.05%/0.02% w/v) solution. All culture media were purchased from Gibco
BRL, Life Technologies and supplements were provided by Biochrom KG Seromed.
4.2.2. Receptor Autoradiography
Binding affinities of N4-GRP(14–27) were determined by in vitro receptor autoradiography
performed on cryostat sections of well characterized human tumor tissues, prostate carcinomas
for GRPR, ileal carcinoids for NMBR and bronchial carcinoids for BB3R, as previously described [23].
The universal radioligand 125I-[DTyr6,βAla11,Phe13,Nle14]BBN(6–14) (2 Ci/mol; ANAWA, Wangen
Switzerland) was used as tracer known to identify all three bombesin receptor subtypes [6]. IC50 values
are given in nM ± SEM.
4.2.3. Competition Binding in PC-3 Cell-Membranes
Competition binding experiments against [125I-Tyr4] BBN were performed with N4-GRP(14–27)
and N4-GRP(18–27), or with the unmodified parent peptide references GRP(14–27) and GRP(18–27)
in PC-3 cell membranes. For the assay, triplicates per concentration point (concentration range:
10−13–10−6 M) of each test peptide were incubated together with the radioligand (~40,000 cpm per
assay tube at a 50 pM concentration) in PC-3 cell-membrane homogenates in a total volume of 300 µL
binding buffer (BB, 50 mM HEPES pH 7.4, 1% BSA, 5.5 mM MgCl2, 35 µM bacitracin) for 1 h at
22 ◦C in an Incubator-Orbital Shaker (MPM Instr. SrI, Bernareggio, Italy). Binding was interrupted by
ice-cold washing buffer (WB, 10 mM HEPES pH 7.4, 150 mM NaCl) and rapid filtration (Whatman
GF/B filters presoaked in BB) on a Brandel Cell Harvester (Adi Hassel Ing. Büro, Munich, Germany).
Filters were washed with ice-cold WB and counted in an automatic well-type gamma counter (NaI(Tl)
3′-crystal, Cobra Packard Auto-Gamma 5000 series instrument). The IC50 values were calculated
using nonlinear regression according to a one-site model applying the PRISM 2 program (Graph Pad
Software, San Diego, CA, USA).
4.2.4. Internalization Assay in PC-3 Cells
The internalization rates of 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) were compared in
PC-3 cells. Briefly, PC-3 cells were seeded in six-well plates (~1 × 106 cells per well) 24 h before
the experiment. Approximately 50,000 cpm of either 99mTc-N4-GRP(14–27) or 99mTc-N4-GRP(18–27)
(corresponding to 250 fmol total peptide in 150 µL of 0.5% BSA/PBS) was added alone (total) or in the
presence of 1 µM [Tyr4]BBN (nonspecific). Cells were incubated at 37 ◦C for 15, 30, 60, and 120 min
and incubation was interrupted each time by placing the plates on ice, removing the supernatants and
rapid rinsing with ice-cold 0.5% BSA/PBS. Cells were then treated 2 × 5 min with acid wash buffer
(2 × 0.6 mL, 50 mM glycine buffer pH 2.8, 0.1 M NaCl) at room temperature and supernatants were
collected (membrane-bound fraction). After rinsing with 1 mL chilled 0.5% BSA/PBS, cells were lysed
by treatment with 1 N NaOH (2 × 0.6 mL) and lysates were collected (internalized fraction). Sample
radioactivity was measured in the γ-counter and percent internalized radioactivity was determined
vs. total added activity. Results represent the average values ± sd of three experiments performed
in triplicate.
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4.3. Animal Studies
4.3.1. In Vivo Stability Tests
For stability experiments, healthy male Swiss albino mice (30 ± 5 g, NCSR “Demokritos” Animal
House Facility) were used. Test radioligand—99mTc-N4-GRP(14–27) or 99mTc-N4-GRP(18–27)—was
injected as a 100 µL bolus (37–74 MBq, 3 nmol total peptide) in the tail vein together with injection
solution (100 µL; control) or with a PA-solution (100 µL injection solution containing 300 µg PA).
Animals were euthanized and blood (0.5–1 mL) was directly withdrawn from the heart in an ice-cold
syringe and transferred in a prechilled EDTA and methionine-containing Eppendorf tube on ice.
Blood samples were centrifuged for 10 min at 2000 g/4 ◦C and plasma was collected. After addition
of an equal volume of ice-cold MeCN the mixture was centrifuged for 10 min at 15,000 g/4 ◦C.
The supernatant was concentrated under a N2-flux at 60 ◦C to 0.05–0.1 mL, diluted with saline (0.4 mL),
filtered through a 0.22 µm Millex GV filter (Millipore, Milford, CT, USA), and analyzed by RP-HPLC.
The Symmetry Shield RP18 (5 µm, 3.9 mm × 20 mm) column was eluted at a flow rate of 1.0 mL/min
with the following linear gradient (system 2): 0% B at 0 min to 10% B in 10 min and then in 40 min
to 30% B; A = 0.1% aq. TFA and B = MeCN. The tR of the intact radiopeptide was determined by
coinjection with the 99mTc-N4-GRP(14–27) and 99mTc-N4-GRP(18–27) reference in the HPLC.
4.3.2. Induction of PC-3 Xenografts in SCID Mice
A suspension containing freshly harvested human PC-3 cells (≈150 µL of a ≈1.2 × 107 cells) was
subcutaneously injected in the flanks of female SCID mice (15 ± 3 g, six weeks of age at the day of
arrival, NCSR “Demokritos” Animal House Facility). The animals were kept under aseptic conditions
and 4 weeks later developed well-palpable tumors (80–200 mg) at the inoculation sites.
4.3.3. Biodistribution in PC-3 Xenograft-Bearing SCID Mice
For the biodistribution study, animals in groups of 4 received via the tail vein a 100 µL bolus
of 99mTc-N4-GRP(14–27) (180–370 kBq, corresponding to 10 pmol total peptide) coinjected either
with injection solution (100 µL; control) or PA-solution (300 µg PA dissolved in 100 µL injection
solution; 4 h + PA), or with excess [Tyr4]BBN (100 µL injection solution containing 50 µg [Tyr4]BBN
for in vivo GRPR-blockade; 4 h block). Animals were euthanized at 1-, 4-, and 24-h pi; in the case of
99mTc-N4-GRP(18–27) two animal groups were included at the 4-h pi interval, namely the control and
PA groups described above. Mice were dissected; samples of blood, tumors, and organs of interest were
collected, weighed, and measured for radioactivity in the gamma counter. Intestines and stomach were
not emptied of their contents. Data was calculated as percent injected dose per gram tissue (%ID/g)
with the aid of standard solutions and represent mean values ± sd, n = 4. All animal experiments were
performed in compliance with national and European guidelines and approved by national authorities
(Prefecture of Athens, EL 25 BIO 021; #1609 and #1610).
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